Indication
Refractory aspergillosis
Refractory aspergillosis refers to an invasive fungal infection caused by *Aspergillus* species that fails to respond or demonstrates clinical progression despite receiving guideline-directed, therapeutic-dose antifungal therapy for an adequate duration. Read more about Refractory aspergillosis
16 drugs 14 manufacturers
Drugs that treat it
Common Refractory aspergillosis therapies.
CANCIDAS (caspofungin acetate)
CASPOFUNGIN ACETATE
CASPOFUNGIN ACETATE
CASPOFUNGIN ACETATE
CASPOFUNGIN ACETATE
CASPOFUNGIN ACETATE
CASPOFUNGIN (caspofungin acetate)
CASPOFUNGIN ACETATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonRefractory aspergillosis refers to an invasive fungal infection caused by *Aspergillus* species that fails to respond or demonstrates clinical progression despite receiving guideline-directed, therapeutic-dose antifungal therapy for an adequate duration.
Primarily manifesting in the lower respiratory tract and adjacent thoracic tissues, it most commonly arises in severely immunocompromised hosts, such as recipients of hematopoietic stem cell or solid organ transplants, individuals with prolonged neutropenia, or patients undergoing intensive antineoplastic chemotherapy.
Clinically and pathophysiologically, the condition is characterized by persistent or worsening symptoms, radiographic progression of angioinvasive tissue necrosis or cavitary lesions, and persistently positive or rising mycological biomarkers such as serum or bronchoalveolar lavage galactomannan.
Underlying mechanisms frequently involve acquired or intrinsic antifungal resistance, suboptimal systemic drug exposure, or irreversible host immune deficiency.
- nih.gov
Refractory aspergillosis refers to an invasive fungal infection caused by *Aspergillus* species that fails to respond or demonstrates clinical progression despite receiving guideline-directed, therapeutic-dose antifungal therapy for an adequate duration Primarily manifesting in the lower respiratory tract and adjacent thoracic tissues, it most commonly arises in severely immunocompromised hosts, such as recipients of hematopoietic stem cell or solid organ transplants, individuals with prolonged ...
- researchgate.net
Refractory aspergillosis refers to an invasive fungal infection caused by *Aspergillus* species that fails to respond or demonstrates clinical progression despite receiving guideline-directed, therapeutic-dose antifungal therapy for an adequate duration Clinically and pathophysiologically, the condition is characterized by persistent or worsening symptoms, radiographic progression of angioinvasive tissue necrosis or cavitary lesions, and persistently positive or rising mycological biomarkers suc...
- uthscsa.edu
Primarily manifesting in the lower respiratory tract and adjacent thoracic tissues, it most commonly arises in severely immunocompromised hosts, such as recipients of hematopoietic stem cell or solid organ transplants, individuals with prolonged neutropenia, or patients undergoing intensive antineoplastic chemotherapy
- merckmanuals.com
Clinically and pathophysiologically, the condition is characterized by persistent or worsening symptoms, radiographic progression of angioinvasive tissue necrosis or cavitary lesions, and persistently positive or rising mycological biomarkers such as serum or bronchoalveolar lavage galactomannan
Personalize your experience
Follow Refractory aspergillosis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.